Literature DB >> 8958752

[A case of myasthenia gravis which developed myasthenic crisis after alpha-interferon therapy for chronic hepatitis C].

T Konishi1.   

Abstract

A 49-year-old man, who developed generalized symptoms of myasthenia gravis at the age of 30 and had thymomectomy, was recently admitted to our hospital for myasthenic crisis after alpha-interferon (IFN) therapy for his chronic hepatitis C. He had shown only mild ocular symptoms before the start of the IFN intramuscular injection therapy. Three months after the IFN therapy (900MU three times a week after 2 weeks of daily injection), he developed generalized weakness, dysarthria, and dysphagia. After the cessation of his IFN therapy, his conditions became worse in parallel with the increase in the titer of anti-acetylcholine receptor antibody. He required artificial ventilation for 2 weeks during myasthenic crisis and he received food and medication through nasogastric tube. He recovered from myasthenic crisis and could eat orally 4 months after the cessation of interferon therapy, but he still suffered from mild bulbar symptoms 8 months after the IFN cessation. IFN therapy should be avoided for the patients with myasthenia gravis, since it may cause myasthenic crisis, and may aggravate myasthenic symptoms for a long period.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958752

Source DB:  PubMed          Journal:  Rinsho Shinkeigaku        ISSN: 0009-918X


  3 in total

1.  Retinopathy is not the only ocular symptom: myasthenia gravis in association with interferon therapy.

Authors:  A Oishi; K Miyamoto; S Kashii; N Yoshimura
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

2.  Myasthenic crisis.

Authors:  Linda C Wendell; Joshua M Levine
Journal:  Neurohospitalist       Date:  2011-01

3.  Myasthenia Crisis Induced by Pegylated-Interferon in Patient With Chronic Hepatitis C: A Case Report.

Authors:  Su Jung Baik; Tae Hun Kim; Hye In Kim; Jeong Yeon Rhie
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.